Peyronie's disease - outcomes of collagenase clostridium histolyticum injection: A systematic review.
Austin T MeffordOmer RaheemFaysal A YafiLaith M AlzweriPublished in: Arab journal of urology (2021)
Since the approval of CCh by the United States Food and Drug Administration in2013, it has been a staple in the treatment of PD, and here we report the continuedsuperiority of this therapy. CCh is an effective, minimally invasive option in most PDpopulations; however, recent changes have made CCh unavailable for commercial use outside the United States, impacting many patients who have previously benefited.
Keyphrases
- drug administration
- minimally invasive
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- stem cells
- mesenchymal stem cells
- climate change
- robot assisted
- skeletal muscle
- replacement therapy
- insulin resistance
- metabolic syndrome
- patient reported
- human health
- glycemic control